Abbvie INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$838Mgeneral payments (2019-2025)
$13Mresearch payments (2019-2025)
458,233clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Botox $34M associated (2023-2025)
- Vraylar $8.9M associated (2023-2025)
- Rinvoq $8.8M associated (2023-2025)
- Skyrizi $5.1M associated (2023-2025)
- Ubrelvy $4.7M associated (2023-2025)
- Qulipta $4.4M associated (2023-2025)
- Durysta $1.2M associated (2023-2025)
- Natrelle Saline-Filled Breast Implants $1.1M associated (2023-2025)
- Venclexta $732K associated (2023-2025)
- Vuity $727K associated (2023-2025)
- Linzess $687K associated (2023-2025)
- Strattice Reconstructive Tissue Matrix Bps $618K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| William Binder | Beverly Hills, CA | Plastic Surgery Within The Head and Neck | $63,479,866.26 |
| George Maxwell | Nashville, TN | Plastic Surgery | $48,249,502.45 |
| Christopher Capelli | Houston, TX | $20,666,688.03 | |
| Ramin Farzaneh-Far | Dallas, TX | Cardiovascular Disease | $17,063,429.22 |
| Jonathan Epstein | Philadelphia, PA | Internal Medicine | $13,127,853.53 |
| Drew Weissman | Philadelphia, PA | Allergy & Immunology (Internal Medicine) | $12,826,686.37 |
| Carl June | Philadelphia, PA | Medical Oncology | $8,978,680.46 |
| Helen Thackray | Washington, DC | Pediatrics | $3,968,074.84 |
| Sam Khalifian | La Mesa, CA | Procedural Dermatology | $3,175,218.47 |
| John Cush | Dallas, TX | Rheumatology | $2,350,049.89 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.